Indian Journal of Endocrinology and Metabolism

BRIEF COMMUNICATION
Year
: 2015  |  Volume : 19  |  Issue : 4  |  Page : 524--528

Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis


Sanjay Kalra1, Rakesh Sahay2, Yashdeep Gupta3 
1 Department of Endocrinology, Bharti Hospital and BRIDE, Karnal, Haryana, India
2 Department of Endocrinology, Osmania Medical College, Hyderabad, Telangana, India
3 Department of Medicine, Government Medical College, Chandigarh, India

Correspondence Address:
Dr. Sanjay Kalra
Department of Endocrinology, Bharti Hospital and BRIDE, Karnal, Haryana
India

Sodium glucose transporter 2 (SGLT2) inhibitors are a recently developed class of drug that have been approved for use in type 2 diabetes. Their unique extra-pancreatic glucuretic mode of action has encouraged their usage in type 1 diabetes as well. At the same time, reports of pseudo ketoacidosis and ketoacidosis related to their use have been published. No clear mechanism for this phenomenon has been demonstrated so far. This communication delves into the biochemical effects of SGLT2 inhibition, discusses the utility of these drugs and proposes steps to maximize safe usage of the molecules.


How to cite this article:
Kalra S, Sahay R, Gupta Y. Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis.Indian J Endocr Metab 2015;19:524-528


How to cite this URL:
Kalra S, Sahay R, Gupta Y. Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis. Indian J Endocr Metab [serial online] 2015 [cited 2021 Sep 19 ];19:524-528
Available from: https://www.ijem.in/article.asp?issn=2230-8210;year=2015;volume=19;issue=4;spage=524;epage=528;aulast=Kalra;type=0